Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

Liu HM, Roberts JA, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS, Oberste MS.

Antimicrob Agents Chemother. 2012 Nov;56(11):5568-74. doi: 10.1128/AAC.00539-12. Epub 2012 Aug 13.

2.

In vitro antiviral activity of V-073 against polioviruses.

Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS.

Antimicrob Agents Chemother. 2009 Oct;53(10):4501-3. doi: 10.1128/AAC.00671-09. Epub 2009 Jul 27.

3.

The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.

Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin SR, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O'Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM.

ChemMedChem. 2008 Oct;3(10):1508-15. doi: 10.1002/cmdc.200800168. No abstract available.

PMID:
18729128
4.

N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.

Bailey TR, Rippin SR, Opsitnick E, Burns CJ, Pevear DC, Collett MS, Rhodes G, Tohan S, Huggins JW, Baker RO, Kern ER, Keith KA, Dai D, Yang G, Hruby D, Jordan R.

J Med Chem. 2007 Apr 5;50(7):1442-4. Epub 2007 Mar 3.

5.

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.

6.

Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses.

Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, Sperzel LE, Jones KF, Warren TK, Amanda Lund S, Kirkwood-Watts DL, King DS, Shurtleff AC, Guttieri MC, Deng Y, Bleam M, Hruby DE.

Antiviral Res. 2006 Feb;69(2):86-97. Epub 2005 Nov 28.

PMID:
16343651
7.

Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.

Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS.

Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9.

8.

Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.

Ledford RM, Collett MS, Pevear DC.

Antiviral Res. 2005 Dec;68(3):135-8. Epub 2005 Sep 19.

PMID:
16199099
9.

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.

Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.

J Virol. 2005 Oct;79(20):13139-49.

10.

Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol.

Wyde PR, Laquerre S, Chetty SN, Gilbert BE, Nitz TJ, Pevear DC.

Antiviral Res. 2005 Oct;68(1):18-26.

PMID:
16112208
11.

Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds.

Zhang Y, Simpson AA, Ledford RM, Bator CM, Chakravarty S, Skochko GA, Demenczuk TM, Watanyar A, Pevear DC, Rossmann MG.

J Virol. 2004 Oct;78(20):11061-9.

12.

Design, expression, and purification of a Flaviviridae polymerase using a high-throughput approach to facilitate crystal structure determination.

Choi KH, Groarke JM, Young DC, Rossmann MG, Pevear DC, Kuhn RJ, Smith JL.

Protein Sci. 2004 Oct;13(10):2685-92.

13.

Newly synthesized hepatitis C virus replicon RNA is protected from nuclease activity by a protease-sensitive factor(s).

Yang G, Pevear DC, Collett MS, Chunduru S, Young DC, Benetatos C, Jordan R.

J Virol. 2004 Sep;78(18):10202-5.

14.

The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation.

Choi KH, Groarke JM, Young DC, Kuhn RJ, Smith JL, Pevear DC, Rossmann MG.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4425-30. Epub 2004 Mar 19.

15.

VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.

Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC.

J Virol. 2004 Apr;78(7):3663-74.

16.

Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.

Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M; Pleconaril Respiratory Infection Study Group.

Clin Infect Dis. 2003 Jun 15;36(12):1523-32. Epub 2003 Jun 6.

PMID:
12802751
17.

A structurally biased combinatorial approach for discovering new anti-picornaviral compounds.

Tsang SK, Cheh J, Isaacs L, Joseph-McCarthy D, Choi SK, Pevear DC, Whitesides GM, Hogle JM.

Chem Biol. 2001 Jan;8(1):33-45.

18.

Mechanism of action of a pestivirus antiviral compound.

Baginski SG, Pevear DC, Seipel M, Sun SC, Benetatos CA, Chunduru SK, Rice CM, Collett MS.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7981-6.

19.

Activity of pleconaril against enteroviruses.

Pevear DC, Tull TM, Seipel ME, Groarke JM.

Antimicrob Agents Chemother. 1999 Sep;43(9):2109-15.

20.

Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants.

Groarke JM, Pevear DC.

J Infect Dis. 1999 Jun;179(6):1538-41.

PMID:
10228078
21.

Human rhinovirus 3 at 3.0 A resolution.

Zhao R, Pevear DC, Kremer MJ, Giranda VL, Kofron JA, Kuhn RJ, Rossmann MG.

Structure. 1996 Oct 15;4(10):1205-20.

22.

Structural studies on human rhinovirus 14 drug-resistant compensation mutants.

Hadfield AT, Oliveira MA, Kim KH, Minor I, Kremer MJ, Heinz BA, Shepard D, Pevear DC, Rueckert RR, Rossmann MG.

J Mol Biol. 1995 Oct 13;253(1):61-73.

PMID:
7473717
23.

The structure of coxsackievirus B3 at 3.5 A resolution.

Muckelbauer JK, Kremer M, Minor I, Diana G, Dutko FJ, Groarke J, Pevear DC, Rossmann MG.

Structure. 1995 Jul 15;3(7):653-67.

24.

[(Biaryloxy)alkyl]isoxazoles: picornavirus inhibitors.

Guiles JW, Diana GD, Pevear DC.

J Med Chem. 1995 Jul 7;38(14):2780-3.

PMID:
7629816
25.

Structures of four methyltetrazole-containing antiviral compounds in human rhinovirus serotype 14.

Giranda VL, Russo GR, Felock PJ, Bailey TR, Draper T, Aldous DJ, Guiles J, Dutko FJ, Diana GD, Pevear DC, McMillan M.

Acta Crystallogr D Biol Crystallogr. 1995 Jul 1;51(Pt 4):496-503.

PMID:
15299836
26.

Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization.

Arruda E, Boyle TR, Winther B, Pevear DC, Gwaltney JM Jr, Hayden FG.

J Infect Dis. 1995 May;171(5):1329-33.

PMID:
7751712
27.

Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism.

Diana GD, Rudewicz P, Pevear DC, Nitz TJ, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FJ, Aldi C, et al.

J Med Chem. 1995 Apr 14;38(8):1355-71.

PMID:
7731021
28.

An evaluation of the antirhinoviral activity of acetylfuran replacements for 3-methylisoxazoles. Are 2-acetylfurans bioisosteres for 3-methylisoxazoles?

Bailey TR, Diana GD, Mallamo JP, Vescio N, Draper TL, Carabateas PM, Long MA, Giranda VL, Dutko FJ, Pevear DC.

J Med Chem. 1994 Nov 25;37(24):4177-84. Erratum in: J Med Chem 1995 Apr 14;38(8):1416.

PMID:
7990117
29.

Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity.

Diana GD, Volkots DL, Nitz TJ, Bailey TR, Long MA, Vescio N, Aldous S, Pevear DC, Dutko FJ.

J Med Chem. 1994 Jul 22;37(15):2421-36.

PMID:
8057290
30.

Human rhinovirus 14 complexed with fragments of active antiviral compounds.

Bibler-Muckelbauer JK, Kremer MJ, Rossmann MG, Diana GD, Dutko FJ, Pevear DC, McKinlay MA.

Virology. 1994 Jul;202(1):360-9.

PMID:
8009848
31.

The structure of human rhinovirus 16.

Oliveira MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, Pevear DC, Dutko FJ, McKinlay MA, et al.

Structure. 1993 Sep 15;1(1):51-68.

PMID:
7915182
32.

Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A.

Mallamo JP, Diana GD, Pevear DC, Dutko FJ, Chapman MS, Kim KH, Minor I, Oliveira M, Rossmann MG.

J Med Chem. 1992 Dec 11;35(25):4690-5.

PMID:
1335081
33.

Antirhinoviral activity of heterocyclic analogs of Win 54954.

Bailey TR, Diana GD, Kowalczyk PJ, Akullian V, Eissenstat MA, Cutcliffe D, Mallamo JP, Carabateas PM, Pevear DC.

J Med Chem. 1992 Nov 27;35(24):4628-33.

PMID:
1335079
34.

CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.

Diana GD, Kowalczyk P, Treasurywala AM, Oglesby RC, Pevear DC, Dutko FJ.

J Med Chem. 1992 Mar 20;35(6):1002-8. Erratum in: J Med Chem 1992 Dec 11;35(25):4768.

PMID:
1313108
35.

Drugs as molecular tools.

Dutko FJ, Baright DE, Diana GD, Fox MP, Pevear DC, McKinlay MA.

Adv Exp Med Biol. 1992;312:15-24. Review. No abstract available.

PMID:
1514439
36.

Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment.

McKinlay MA, Pevear DC, Rossmann MG.

Annu Rev Microbiol. 1992;46:635-54. Review.

PMID:
1332585
37.

A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.

Diana GD, Treasurywala AM, Bailey TR, Oglesby RC, Pevear DC, Dutko FJ.

J Med Chem. 1990 May;33(5):1306-11.

PMID:
2158559
38.

Localization of genomic regions specific for the attenuated, mouse-adapted poliovirus type 2 strain W-2.

Pevear DC, Oh CK, Cunningham LL, Calenoff M, Jubelt B.

J Gen Virol. 1990 Jan;71 ( Pt 1):43-52.

PMID:
2154539
39.

Crystal structure of human rhinovirus serotype 1A (HRV1A).

Kim SS, Smith TJ, Chapman MS, Rossmann MC, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA.

J Mol Biol. 1989 Nov 5;210(1):91-111.

PMID:
2555523
40.

Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.

Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ.

J Virol. 1989 May;63(5):2002-7.

41.

Inhibitors of viral uncoating.

Diana GD, Pevear DC, Otto MJ, McKinlay MA, Rossmann MG, Smith T, Badger J.

Pharmacol Ther. 1989;42(3):289-305. Review. No abstract available.

PMID:
2672048
42.

Insights into Theiler's virus neurovirulence based on a genomic comparison of the neurovirulent GDVII and less virulent BeAn strains.

Pevear DC, Borkowski J, Calenoff M, Oh CK, Ostrowski B, Lipton HL.

Virology. 1988 Jul;165(1):1-12.

PMID:
2838951
45.

Characterization and specificity of humoral immune responses to Theiler's murine encephalomyelitis virus capsid proteins.

Clatch RJ, Pevear DC, Rozhon E, Roos RP, Miller SD, Lipton HL.

J Gen Virol. 1987 Dec;68 ( Pt 12):3191-6.

PMID:
2826657
46.
49.

Severe and transient pancytopenia associated with a chronic arenavirus infection.

Broomhall KS, Morin M, Pevear DC, Pfau CJ.

J Exp Pathol. 1987;3(3):259-69.

PMID:
2835466
50.

Lymphocytic choriomeningitis virus-induced disease of the central nervous system and the "antigen-sink" hypothesis.

Pevear DC, Melio F, Pfau CJ.

Med Microbiol Immunol. 1986;175(2-3):205-8. No abstract available.

PMID:
3487710

Supplemental Content

Loading ...
Support Center